Search

Your search keyword '"Taxonera C"' showing total 453 results
Start Over Author "Taxonera C"
453 results on '"Taxonera C"'

1. Differential association of two PTPN22 coding variants with Crohn’s disease and ulcerative colitis

Author

Weersma R K, Roberts R L, Gearry R B, Ponsioen C Y, Wijmenga C, van Bodegraven A A, Crusius J B, Barclay M L, Bottini N, López-Nevot M A, Cueto I, Nieto A, Alcain G, Taxonera C, Mendoza J L, Rodrigo L, Cardeña C, van Sommeren S, Gómez-García M, Fransen K, Espino-Paisán L, Diaz-Gallo L M, Urcelay E, Merriman T R, Alizadeh B Z, and Martin J

Subjects
Medicine
Published
2010
Full Text
View/download PDF

2. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

Author

Merino, O., Hernández-Camba, A., Arranz, L., Vera, I., Carpio, D., Calafat, M., Lucendo, A.J., Taxonera, C., Marín, S., Garcia, M.J., Marín, G. Suris, Rodríguez, E. Sánchez, Carbajo, A.Y., De Castro, M.L., Iborra, M., Martin-Cardona, A., Rodríguez-Lago, I., Busquets, D., Bertoletti, F., Ausín, M. Sierra, Tardillo, C., Malaves, J. Huguet, Bujanda, L., Castaño, A., Domènech, E., and Ramos, L.

Published
2022
Full Text
View/download PDF

3. P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

Author

Madero Velázquez, L, primary, De Francisco, R, additional, Herreros, B, additional, Yagüe, C, additional, Bujanda, L, additional, Calvet, X, additional, Ponferrada, A, additional, Aguas, M, additional, Rodríguez-Moranta, F, additional, Marin- Jiménez, I, additional, Catala, L, additional, Gomollon, F, additional, Huguet, J, additional, Mesonero, F, additional, Monfort, D, additional, Sierra, M, additional, Igualada, L, additional, Ricart, E, additional, González-Vivó, M, additional, García, M J, additional, Hernandez- Camba, A, additional, Elorza, A, additional, Zabalza- San Martín, L, additional, Ramos, L, additional, Martín Arranz, M D, additional, Ruiz-Nuñez, I, additional, Martinez-Montiel, P, additional, Soto, P, additional, Roig, C, additional, Molina, M L, additional, Mañona, M, additional, Taxonera, C, additional, Barreiro- de Acosta, M, additional, Gisbert, J P, additional, Ramírez, P, additional, Lorente, R, additional, Zabana, Y, additional, Botella, B, additional, Domènech, E, additional, and Gutierrez-Casbas, A, additional

Published
2024
Full Text
View/download PDF

4. DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA

Author

Rubín De Célix, C, primary, Ricart, E, additional, Martín-Arranz, M D, additional, Pérez-Martínez, I, additional, Barrio, J, additional, Mesonero, F, additional, Gomollón, F, additional, de Castro, L, additional, Ramos, L, additional, García-López, S, additional, Arias, L, additional, Mañosa, M, additional, Iglesias, E, additional, Calvet, X, additional, Pascual, I, additional, Casanova, M J, additional, Pérez-Calle, J L, additional, Giordano, A, additional, Sierra, M, additional, Vera, I, additional, Navarro-Llavat, M, additional, Lorente, R, additional, Piqueras, M, additional, Rivero, M, additional, Guardiola, J, additional, Esteve, M, additional, Fuentes Coronel, A, additional, Rodríguez-Lago, I, additional, Ponferrada, Á, additional, Ber, Y, additional, Tardillo, C, additional, Márquez, L, additional, Carpio, D, additional, Taxonera, C, additional, Bermejo, F, additional, Busquets, D, additional, Camps, B, additional, Domènech, E, additional, Chaparro, M, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

5. P1115 Characteristics and management of pyoderma gangrenosum and erythema nodosum in patients with inflammatory bowel disease: PIONOSO multicenter study

Author

Rodríguez-Lago, I, primary, Vela, M, additional, Ordás, I, additional, de Francisco, R, additional, Martín-Arranz, M D, additional, Calafat, M, additional, Taxonera, C, additional, Mesonero, F, additional, Fuentes-Valenzuela, E, additional, Granja, A, additional, Ponferrada-Díaz, Á, additional, Varela, P, additional, Zabana, Y, additional, Madero, L, additional, López-Cauce, B, additional, Carrillo, M, additional, Laredo, V, additional, Brunet, E, additional, Rivero, M, additional, Polo, C, additional, Gisbert, J P, additional, Rodríguez, C, additional, Suria, C, additional, Lorente, R, additional, Elorza, A, additional, Sicilia, B, additional, Muñoz-Villafranca, M D C, additional, Mínguez, A, additional, Ferreiro-Iglesias, R, additional, Pajares, R, additional, Castro-Poceiro, J, additional, Surís, G, additional, Roig, C, additional, Mena, R, additional, Lucendo, A J, additional, de la Peña, L, additional, Iyo, E, additional, Ber, Y, additional, Domènech, E, additional, and Barreiro-de Acosta, M, additional

Published
2024
Full Text
View/download PDF

6. P987 Impact of Crohn’s Disease Location on Biologic Therapy Persistence and the Risk of Intestinal Surgery: Insights from the ENEIDA Registry (the DISCOLOC Study)

Author

Giordano, A, primary, Pérez Martínez, I, additional, Gisbert, J P, additional, Ricart, E, additional, M Dolores, M A, additional, Mesonero, F, additional, M Luisa, D C P, additional, Rivero, M, additional, Iglesias Flores, E, additional, Fernández-Prada, S, additional, Calafat, M, additional, Arroyo Villarino, M, additional, de Jorge Turrión, M Á, additional, Rodríguez-González, E, additional, Corsino Roche, P, additional, Carpio, D, additional, Brunet, E, additional, Rodriguez Moranta, F, additional, Arias García, L, additional, Pascual, I, additional, Bermejo, F, additional, Madero, L, additional, Esteve, M, additional, González Muñoza, C, additional, Martínez-Montiel, P, additional, Huguet, J M, additional, Pérez Calle, J L, additional, Rodríguez-Lago, I, additional, Sierra Ausín, M, additional, Lorente Poyatos, R H, additional, García-Bosch, O, additional, Surís Marín, G, additional, Taxonera, C, additional, Ponferrada-Díaz, Á, additional, Barreiro-de Acosta, M, additional, Bujanda, L, additional, Blat Serra, R, additional, Ramos, L, additional, Domènech, E, additional, and Garcia Planella, E, additional

Published
2024
Full Text
View/download PDF

7. P211 Impact of celiac disease on the outcome of Inflammatory Bowel Disease

Author

Alonso, I, primary, Ramos, L, additional, Hernández-Camba, A, additional, Yagüe-Caballero, C, additional, Vicente Lidón, R, additional, Taxonera, C, additional, García-Brenes, M A, additional, Gisbert, J P, additional, Chaparro, M, additional, Madero Velázquez, L, additional, Carrillo-Palau, M, additional, Arranz Hernández, L, additional, Castro Senosiain, B, additional, García de la Filia Molina, I, additional, Rojas-Feria, M, additional, López Romero-Salazar, F, additional, Bastón-Rey, I, additional, Sánchez-Azofra, M, additional, Riestra, S, additional, Pérez-Galindo, P, additional, Ortega Moya, S P, additional, Brunet-Mas, E, additional, Sanz Segura, P, additional, Caballero-Mateos, A M, additional, Calafat, M, additional, Botella Mateu, B, additional, Manceñido Marcos, N, additional, Rodríguez-Lago, I, additional, Suárez-Ferrer, C, additional, and Gutiérrez Casbas, A, additional

Published
2024
Full Text
View/download PDF

10. OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO

Author

D'Haens, G, primary, Taxonera, C, additional, Lopez-Sanroman, A, additional, Nos Mateu, P, additional, Danese, S, additional, Armuzzi, A, additional, Roblin, X, additional, Peyrin-Biroulet, L, additional, West, R, additional, Witteman, B, additional, Duijvestein, M, additional, Gecse, K, additional, Hulshoff, M, additional, Mostafavi, N, additional, Clasquin, E, additional, Bouhnik, Y, additional, and Laharie, D, additional

Published
2023
Full Text
View/download PDF

11. P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA

Author

Gargallo-Puyuelo, C, primary, Ricard, E, additional, Iborra, M, additional, Iglesias-Flores, E, additional, Vera Mendoza, I, additional, De Francisco García, R, additional, Calafat Sard, M, additional, Minguez, M, additional, Lopez- San Roman, A, additional, Taxonera, C, additional, Guardiola, J, additional, Barrio, J, additional, Laredo, V, additional, De Castro, L, additional, Gisbert, J, additional, García-Lopez, S, additional, García Planella, E, additional, Martín Arranz, D, additional, Calvet, X, additional, Merino, O, additional, Sierra, M, additional, Marquez, L, additional, Madero, L, additional, Varela, P, additional, Carpio, D, additional, Esteve, M, additional, Rivero, M, additional, Ramos, L, additional, Sicilia, B, additional, Lorente POyatos, R, additional, Marin, I, additional, Monfort, D, additional, Navarro, M, additional, VEga, P, additional, Hinojosa, J, additional, Tardillo, C, additional, García Sepulcre, M F, additional, Barreiro, M, additional, Domenech, E, additional, and Gomollón, F, additional

Published
2023
Full Text
View/download PDF

15. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry

Author

Calafat, M, Mañosa, M, Cañete, F, Panés, J, García Sánchez, V, Calvo, M, Rodríguez-Moranta, F, Taxonera, C, Nos, P, López Sanromán, A, Martín Arranz, M D, Mínguez, M, Gisbert, J P, García-López, S, de Francisco, R, Gomollón, F, Calvet, X, Garcia-Planella, E, Rivero, M, Martínez-Cadilla, J, Argüelles, F, Arias García, L, Cimavilla, M, Zabana, Y, Márquez, L, Gutiérrez, A, Alcaín, G, Martínez Montiel, P, Lázaro, J, Busquets, D, García Sepulcre, M F, Verdejo, C, Bermejo, F, Mora, M, Monfort, D, Romero, P, Velayos, B, Rodríguez, C, Rodríguez, A, Merino, O, Rodríguez-Pescador, A, Bujanda, L, Ber, Y, Vela, M, Roncero, O, Huguet, J M, García-Bosch, O, Barreiro-de-Acosta, M, Madrigal, R E, Ramos, L, Van Domselaar, M, Almela, P, Llaó, J, Lucendo, A J, Muñoz Vilafranca, C, Abad, À, Charro, M, Legido, J, Riera, J, Khorrami, S, Sesé, E, Trapero, A M, and Domènech, E

Published
2018
Full Text
View/download PDF

17. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

Author

Hernández-Camba, A., primary, Arranz, L., additional, Vera, I., additional, Carpio, D., additional, Calafat, M., additional, Lucendo, A.J., additional, Taxonera, C., additional, Marín, S., additional, Garcia, M.J., additional, Marín, G. Suris, additional, Rodríguez, E. Sánchez, additional, Carbajo, A.Y., additional, De Castro, M.L., additional, Iborra, M., additional, Martin-Cardona, A., additional, Rodríguez-Lago, I., additional, Busquets, D., additional, Bertoletti, F., additional, Ausín, M. Sierra, additional, Tardillo, C., additional, Malaves, J. Huguet, additional, Bujanda, L., additional, Castaño, A., additional, Domènech, E., additional, Ramos, L., additional, and Merino, O., additional

Published
2022
Full Text
View/download PDF

18. P327 Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study

Author

Benítez, J.M., Barreiro-de Acosta, M., Chaparro, M., Vázquez, J.M., Iglesias-Flores, E., Tosca, J., García-Planella, E., García-Lpez, S., Taxonera, C., Muñoz-Villafranca, M., Pajares, R., Barrio, J., Arias, L., Nantes, O., Fernández-Salazar, L., Hervías, D., Martín-Arranz, M., Mesonero, F., Moraleja-Yudejo, I., Pineda, J., Argüelles-Arias, F., Huguet, J., Hernández-Martínez, A., Pérez-Calle, J., Leo, E., Merino, O., Van Domselaar, M., Gutiérrez, A., Lorente, R., Castro, M., Algaba, A., Castro, E., Robles-Alonso, V., Ceballos, D., Gmez-García, R., Domínguez, J., Fernández, E., Vega-Lpez, A., Trapero, A., Talavera, A., Royo, V., Gisbert, J.P., and García-Sánchez, V.

Published
2017
Full Text
View/download PDF

20. DOP063 Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients

Author

Taxonera, C., Ponferrada, A., Bermejo, F., Gisbert, J.P., Riestra, S., Saro, C., Cabriada, J.L., Barreiro-de Acosta, M., Barrio, J., Flores, E., Ferrer, I., Hernandez, A., Van Domselaar, M., Olivares, D., Alba, C., Fernández-Salazar, L., Merino, O., Botella, B., Ceballos, D., Moral, I., Peñate, M., and Algaba, A.

Published
2017
Full Text
View/download PDF

22. DOP016 Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study

Author

Chaparro, M., Verreth, A., Lobaton, T., Gravito-Soares, E., Julsgaard, M., Savarino, E., Magro, F., Avni Biron, I., Lpez-Serrano, P., Casanova, M., Gompertz, M., Vitor, S., Arroyo, M., Pugliese, D., Zabana, Y., Vicente, R., Aguas, M., Bar-Gil Shitrit, A., Gutierrez, A., Doherty, G., Fernández-Salazar, L., Martinez Cadilla, J., Huguet, J., OʼToole, A., Stasi, E., Manceñido Marcos, N., Villoria, A., Karmiris, K., Rahier, J., Rodriguez, C., Diz-Lois Palomares, M., Fiorino, G., Benítez, J., Principi, M., Naftali, T., Taxonera, C., Mantzaris, G., Sebkova, L., Iade, B., Lissner, D., Ferrer Bradley, I., Lpez-San Román, A., Marín-Jiménez, I., Merino, O., Sierra, M., Van Domselaar, M., Caprioli, F., Guerra, I., Peixe, P., Piqueras, M., Rodríguez-Lago, I., Ber, Y., Van Hoeve, K., Torres, P., Gravito-Soares, E., Rudbeck-Thomsen, D., Bartolo, O., Peixoto, A., Martín, G., Pérez, J., Garre, A., Donday, M.G., Martín de Carpi, J., and Gisbert, J.P.

Published
2017
Full Text
View/download PDF

24. Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry

Author

Munoza, CG, Calafat, M, Gisbert, JP, Iglesias, E, Minguez, M, Sicilia, B, Esteve, M, Gomollon, F, Calvet, X, Ricart, E, Carpio, D, Rivero, M, Lopez-Sanroman, A, Marquez, L, Nos, P, Cabriada, JL, Guardiola, J, Garcia-Sepulcre, MF, Garcia-Lopez, S, Poyatos, RL, Taxonera, C, Andres, JB, Vera, I, Domenech, E, and Garcia-Planella, E

Published
2022

25. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

Author

Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, Gisbert JP, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, Lucendo AJ, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de-Acosta M, Sicilia B, Barrio J, Pérez JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, de Zarate JO, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu, [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa, and Universidad de Sevilla. Departamento de Medicina

Subjects
index, Pronòstic mèdic, Risk factors in diseases, COVID-19 (Malaltia), Article, Inflammatory bowel disease, Comorbiditat, inflammatory bowel disease, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity [PUBLIC HEALTH], Factors de risc en les malalties, SARS-CoV-2, COVID-19, determinants, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Prognosis, enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES], infection, epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad [SALUD PÚBLICA], Medicine, Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES], Intestins - Inflamació
Abstract

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged >= 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having >= 2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. This study is funded by the Carlos III Health Institute (COV20/00227: Co-IP Dra. Maria Esteve and Dra. Yamile Zabana), FEDER (Fondo Europeo de Desarrollo Regional) and supported by GETECCU. The ENEIDA Registry of GETECCU is supported by Takeda, Pfizer, Galapagos, AbbVie and Biogen.

Published
2022

26. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

Author

Taxonera C, Fernandez-Acenero M, Olivares D, Calvo M, Casis B, Bermejo F, Serrano P, Iborra M, Mesonero F, Watts M, del Arco C, Vera I, Olivares S, Algaba A, and Alba C

Subjects
therapeutic drug monitoring, histologic remission, golimumab, pharmacokinetic, disease clearance, endoscopic healing, ulcerative colitis
Abstract

Background Optimal thresholds for golimumab concentrations during maintenance for important outcomes are lacking. Aim The aim of the study was to investigate the association of golimumab trough concentrations during maintenance with key outcomes, including endoscopic and histologic remission, and long-term event-free persistence with golimumab, in patients with UC. Methods This multicentre, cross-sectional study included UC patients on golimumab maintenance recruited either in remission or during a flare. Colonoscopy was scheduled, and study-specific rectocolonic biopsies were taken for blind central histologic reading. Samples for golimumab trough concentrations were collected close to colonoscopy. Results Fifty-two patients were included. Median golimumab trough concentrations (mu g/ml) were significantly higher in patients who had clinical remission (2.01 vs. 0.72, p = 0.047), combined clinical-biochemical remission (PMS

Published
2022

27. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

Author

Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-SanRomán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, García-Sepulcre MF, Monfort D, Cañete F, and Domènech E

Subjects
Elderly, inflammatory bowel disease, adverse events
Abstract

BACKGROUND AND AIMS: Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related adverse events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly patients. We aimed to compare the rates of IFX-related IAEs and loss of response [LOR] in elderly and younger patients. METHODS: Adult patients in the ENEIDA registry who had received a first course of IFX therapy were identified and grouped into two cohorts regarding age at the beginning of treatment [over 60 years and between 18 and 50 years]. The rates of IAEs and LOR were compared. RESULTS: In total, 939 patients [12%] who started IFX over 60 years of age and 6844 [88%] below 50 years of age were included. Elderly patients presented a higher proportion of AEs related to IFX [23.2% vs 19%; p = 0.002], infections [7.1% vs 4.3%; p < 0.001] and neoplasms [2.2% vs 0.5%; p < 0.001]. In contrast, the rates of IAEs [14.8% vs 14.8%; p = 0.999], infusion reactions [8.1% vs 8.1%; p = 0.989], late hypersensitivity [1.3% vs 1.2%; p = 0.895], paradoxical psoriasis [1% vs 1.5%; p = 0.187] and drug-induced lupus erythematosus [0.6% vs 0.7%; p = 0.947] were similar in elderly and younger patients. LOR rates were also similar between the two groups [20.5% vs 19.3%; p = 0.438]. In the logistic regression analysis, IFX monotherapy, extraintestinal manifestations and female gender were the only risk factors for IAEs, whereas IFX monotherapy, extraintestinal manifestations and Crohn's disease were risk factors for LOR. CONCLUSIONS: Elderly patients with inflammatory bowel disease have a similar risk of developing IFX-related IAEs and LOR to that of younger patients.

Published
2022

28. P654 Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry

Author

González Muñoza, C, primary, Calafat, M, additional, Gisbert, J P, additional, Iglesias, E, additional, Minguez, M, additional, Sicilia, B, additional, Esteve, M, additional, Gomollon, F, additional, Calvet, X, additional, Ricart, E, additional, Carpio, D, additional, Rivero, M, additional, Lopez-Sanroman, A, additional, Marquez, L, additional, Nos, P, additional, Cabriada, J L, additional, Guardiola, J, additional, Garcia-Sepulcre, M F, additional, Garcia-Lopez, S, additional, Lorente Poyatos, R, additional, Taxonera, C, additional, Barrio Andres, J, additional, Vera, I, additional, Domenech, E, additional, and Garcia-Planella, E, additional

Published
2022
Full Text
View/download PDF

29. Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

Author

Chaparro, M., Zanotti, C., Burgueño, P., Vera, I., Bermejo, F., Marín-Jiménez, I., Yela, C., López, P., Martín, M. D., Taxonera, C., Botella, B., Pajares, R., Ponferrada, A., Calvo, M., Algaba, A., Pérez, L., Casis, B., Maté, J., Orofino, J., Lara, N., García-Losa, M., Badia, X., and Gisbert, J. P.

Published
2013
Full Text
View/download PDF

30. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study

Author

Zabana Abdo, Y, primary, Marín-Jiménez, I, additional, Rodríguez-Lago, I, additional, Vera, I, additional, Martín, M D, additional, Guerra, I, additional, Gisbert, J P, additional, Mesonero, F, additional, Benítez, O, additional, Taxonera, C, additional, Ponferrada-Díaz, Á, additional, Piqueras, M, additional, Lucendo, A, additional, Caballol, B, additional, Mañosa, M, additional, Martínez-Montiel, P, additional, Bosca-Watts, M, additional, Gordillo, J, additional, Bujanda, L, additional, Manceñido, N, additional, Martínez-Pérez, T, additional, López, A, additional, Rodríguez, C, additional, García-López, S, additional, Vega, P, additional, Rivero, M, additional, Melcarne, L, additional, Calvo, M, additional, Iborra, M, additional, Barreiro-de Acosta, M, additional, Arias, L, additional, Barrio, J, additional, Pérez, J L, additional, Busquets, D, additional, Pérez-Martínez, I, additional, Navarro-Llavat, M, additional, Hernández, V, additional, Argüelles-Arias, F, additional, Domènech, E, additional, and Esteve, M, additional

Published
2021
Full Text
View/download PDF

31. Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study

Author

Abdo, YZ, Marin-Jimenez, I, Rodriguez-Lago, I, Vera, I, Martin, MD, Guerra, I, Gisbert, JP, Mesonero, F, Benitez, O, Taxonera, C, Ponferrada-Diaz, A, Piqueras, M, Lucendo, A, Caballol, B, Manosa, M, Martinez-Montiel, P, Bosca-Watts, M, Gordillo, J, Bujanda, L, Mancenido, N, Martinez-Perez, T, Lopez, A, Rodriguez, C, Garcia-Lopez, S, Vega, P, Rivero, M, Melcarne, L, Calvo, M, Iborra, M, Barreiro-de Acosta, M, Arias, L, Barrio, J, Perez, JL, Busquets, D, Perez-Martinez, I, Navarro-Llavat, M, Hernandez, V, Arguelles-Arias, F, Domenech, E, and Esteve, M

Published
2021

32. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry

Author

Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-SanRomán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, García-Sepulcre MF, Monfort D, Cañete F, Domènech E, and ENEIDA Study Group of GETECCU

Subjects
Adult, Gastroenterology, General Medicine, Middle Aged, Inflammatory Bowel Diseases, adverse events, Infliximab, Cohort Studies, Elderly, Treatment Outcome, Gastrointestinal Agents, inflammatory bowel disease, Chronic Disease, Humans, Female, Registries, Aged, Retrospective Studies
Abstract

Background and Aims Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related adverse events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly patients. We aimed to compare the rates of IFX-related IAEs and loss of response [LOR] in elderly and younger patients. Methods Adult patients in the ENEIDA registry who had received a first course of IFX therapy were identified and grouped into two cohorts regarding age at the beginning of treatment [over 60 years and between 18 and 50 years]. The rates of IAEs and LOR were compared. Results In total, 939 patients [12%] who started IFX over 60 years of age and 6844 [88%] below 50 years of age were included. Elderly patients presented a higher proportion of AEs related to IFX [23.2% vs 19%; p = 0.002], infections [7.1% vs 4.3%; p < 0.001] and neoplasms [2.2% vs 0.5%; p < 0.001]. In contrast, the rates of IAEs [14.8% vs 14.8%; p = 0.999], infusion reactions [8.1% vs 8.1%; p = 0.989], late hypersensitivity [1.3% vs 1.2%; p = 0.895], paradoxical psoriasis [1% vs 1.5%; p = 0.187] and drug-induced lupus erythematosus [0.6% vs 0.7%; p = 0.947] were similar in elderly and younger patients. LOR rates were also similar between the two groups [20.5% vs 19.3%; p = 0.438]. In the logistic regression analysis, IFX monotherapy, extraintestinal manifestations and female gender were the only risk factors for IAEs, whereas IFX monotherapy, extraintestinal manifestations and Crohn’s disease were risk factors for LOR. Conclusions Elderly patients with inflammatory bowel disease have a similar risk of developing IFX-related IAEs and LOR to that of younger patients.

Published
2021

33. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Kucharzik, T, Ellul, P, Greuter, T, Rahier, Jean-François, Verstockt, B, Abreu, C, Albuquerque, A, Alloca, M, Esteve, M, Farraye, F A, Gordon, H, Karmiris, K, Kopylov, U, Kirchgesner, J, MacMahon, E, Magro, F, Maaser, C, de Ridder, L, Taxonera, C, Toruner, M, Tremblay, L, Scharl, M, Viget, N, Zabana, Y, Vavricka, S, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Kucharzik, T, Ellul, P, Greuter, T, Rahier, Jean-François, Verstockt, B, Abreu, C, Albuquerque, A, Alloca, M, Esteve, M, Farraye, F A, Gordon, H, Karmiris, K, Kopylov, U, Kirchgesner, J, MacMahon, E, Magro, F, Maaser, C, de Ridder, L, Taxonera, C, Toruner, M, Tremblay, L, Scharl, M, Viget, N, Zabana, Y, and Vavricka, S

Published
2021

35. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease

Author

Kucharzik, T, primary, Ellul, P, additional, Greuter, T, additional, Rahier, J F, additional, Verstockt, B, additional, Abreu, C, additional, Albuquerque, A, additional, Allocca, M, additional, Esteve, M, additional, Farraye, F A, additional, Gordon, H, additional, Karmiris, K, additional, Kopylov, U, additional, Kirchgesner, J, additional, MacMahon, E, additional, Magro, F, additional, Maaser, C, additional, de Ridder, L, additional, Taxonera, C, additional, Toruner, M, additional, Tremblay, L, additional, Scharl, M, additional, Viget, N, additional, Zabana, Y, additional, and Vavricka, S, additional

Published
2021
Full Text
View/download PDF

36. Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

Author

Chaparro, M, Garre, A, Mesonero, F, Rodriguez, C, Barreiro-de Acosta, M, Martinez-Cadilla, J, Arroyo, MT, Mancenido, N, Sierra-Ausin, M, Vera-Mendoza, I, Casanova, MJ, Nos, P, Gonzalez-Munoza, C, Martinez, T, Bosca-Watts, M, Busquets, D, Calafat, M, Girona, E, Llao, J, Martin-Arranz, MD, Piqueras, M, Ramos, L, Suis, G, Bermejo, F, Carbajo, AY, Casas-Deza, D, Fernandez-Clotet, A, Garcia, MJ, Ginard, D, Gutierrez-Casbas, A, Hernandez-Villalba, L, Lucendo, AJ, Marquez, L, Merino-Ochoa, O, Rancel, FJ, Taxonera, C, Sanroman, AL, Rubio, S, Domenech, E, and Gisbert, JP

Published
2020

38. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

Author

Chaparro M, Guerra I, Iborra M, Cabriada J, Bujanda L, Taxonera C, Garcia-Sanchez V, Marin-Jimenez I, Barreiro-de Acosta M, Vera I, Martin-Arranz M, Hernandez-Breijo B, Mesonero F, Sempere L, Gomollon F, Hinojosa J, Bermejo F, Beltran B, Pescador A, Banales J, Olivares D, Aguilar-Melero P, Menchen L, Ferreiro-Iglesias R, Gomez I, Garcia B, Guijarro L, Marin A, Bernardo D, Gisbert J, and PREDICROHN Study Grp GETECCU

Subjects
Crohn's disease, adalimumab, infliximab, tumor necrosis factor-alpha, trough levels
Abstract

Aims The aims of this study were (a) to know the kinetics of antitumor necrosis factor (TNF) drug serum levels during the induction phase in patients with Crohn's disease; (b) to identify variables associated with these levels; and (c) to assess the relation between these levels and short-term effectiveness in Crohn's disease patients. Methods Patients with Crohn's disease naive to anti-TNF treatment were prospectively included. Remission was defined as a Crohn's disease activity index (CDAI) score 150 at study entry. At week 14, 52 out of 71 patients with CDAI > 150 at baseline (73%) had clinical remission. There were no differences in infliximab levels between patients with and without remission (8 vs. 9.1 mu g/mL, P > 0.05) or with and without response (7 vs. 11 mu g/mL, P > 0.05) at week 14. There was a trend to higher levels of adalimumab concentration in responders in comparison with nonresponders (13 vs. 6.7 mu g/mL, P = 0.05) and in patients who achieved remission in comparison with nonremitters (13.5 vs. 8.4 mu g/mL, P = 0.06). In the multivariate analysis, no variable was predictive of short-term remission, including infliximab and adalimumab serum levels. Conclusion Determining anti-TNF serum levels during the induction phase is not useful for predicting short-term remission in patients with Crohn's disease.

Published
2020

39. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

Author

Iborra, M, Garcia-Morales, N, Rubio, S, Bertoletti, F, Calvo, M, Taxonera, C, Bosca-Watts, MM, Sierra, M, Mancenido, N, Beltran, B, Castillejo, ON, Garcia-Planella, E, Vera, I, Alba, C, Marti-Aguado, D, Ballester, MP, Cano-Sanz, N, Pajares-Villarroya, R, Cerrillo, E, Canada, A, and Nos, P

Abstract

Golimumab has demonstrated its long-term efficacy and safety in ulcerative colitis in clinical trials, but no data of long-term persistence has been published from real world. To estimate long-term persistence of golimumab, as well as factors associated with longer persistence, in patients with ulcerative colitis in real life. Observational multicentre study including adult patients with ulcerative colitis treated with golimumab and with at least twelve months of follow-up. We included 190 patients, 105 (55.26%) naive to anti-TNF, with mean disease duration of 9.32 +/- 8.09 years. Probability of persistence was 63%, 46%, 39% and 27% at 1, 2, 3 and 4 years, respectively. Persistence was lower in patients with primary failure to previous anti-TNF. Eighty-two (43.16%) patients needed dose intensification during follow-up, with a mean time until intensification of 8.03 +/- 8.64 months. Dose intensification and lower disease duration predicted higher persistence with golimumab (p=0.037 and p=0.008, respectively). During a follow-up of 17.25 +/- 15.83 months, 32 (16.5%) patients needed hospitalisation and 11 (6%) underwent colectomy. No unexpected adverse events were reported. Golimumab has demonstrated good persistence and safety profile for long treatment in ulcerative colitis patients.

Published
2020

40. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Author

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, and GETECCU study group

Subjects
Adult, Male, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Communicable Diseases, Inflammatory bowel disease, Vedolizumab, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Interquartile range, Internal medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, Registries, Adverse effect, Prospective cohort study, Hepatology, business.industry, Proportional hazards model, Remission Induction, Gastroenterology, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, Discontinuation, Treatment Outcome, Spain, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, business, Follow-Up Studies, medicine.drug
Abstract

Background: Effectiveness of vedolizumab in real world clinical practice is unknown. Aim: To evaluate the short and long-term effectiveness of vedolizumab in patients with inflammatory bowel disease (IBD). Methods: Patients who received at least 1 induction dose of vedolizumab were included. Effectiveness was defined based on Harvey-Bradshaw index (HBI) in Crohn's disease (CD) and Partial Mayo Score (PMS) in ulcerative colitis (UC). Short-term response was assessed at week 14. Variables associated with short-term remission were identified by logistic regression analysis. The Kaplan-Meier method was used to evaluate the long-term durability of vedolizumab treatment. Cox model was used to identify factors associated with discontinuation of treatment and loss of response. Results: 521 patients were included (median follow-up 10 months [interquartile range 5-18 months]). At week 14, 46.8% had remission and 15.7% clinical response. CD (vs UC), previous surgery, higher CRP concentration and disease severity at baseline were significantly associated with impaired response. The rate of vedolizumab discontinuation was 37% per patient-year of follow-up (27.6% in UC and 45.3% in CD, P < 0.01). CD (vs UC), anaemia at baseline, steroids during induction and CRP concentration were associated with lower durability of treatment. Seven per cent of patients developed adverse events, infections being the most frequent. Conclusions: Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short- and long-term response. Vedolizumab seems to be safe in clinical practice.

Published
2018

41. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

Author

Eliadou, E., Moleiro, J., Ribaldone, D.G., Astegiano, M., Rothfuss, K., Taxonera, C., Ghalim, F., Carbonnel, F., Verstockt, B., Festa, S., Maia, L., Berrozpe, A., Zagorowicz, E., Savarino, E., Ellul, P., Vavricka, S.R., Calvo, M., Koutroubakis, I., Hoentjen, F., Salazar, L.F., Callela, F., Pizarro, F.C., Soufleris, K., Sonnenberg, E., Cavicchi, M., Wypych, J., Hommel, C., Ghiani, A., Fiorino, G., Eliadou, E., Moleiro, J., Ribaldone, D.G., Astegiano, M., Rothfuss, K., Taxonera, C., Ghalim, F., Carbonnel, F., Verstockt, B., Festa, S., Maia, L., Berrozpe, A., Zagorowicz, E., Savarino, E., Ellul, P., Vavricka, S.R., Calvo, M., Koutroubakis, I., Hoentjen, F., Salazar, L.F., Callela, F., Pizarro, F.C., Soufleris, K., Sonnenberg, E., Cavicchi, M., Wypych, J., Hommel, C., Ghiani, A., and Fiorino, G.

Abstract

Contains fulltext : 220103.pdf (Publisher’s version ) (Closed access), BACKGROUND: Interstitial lung [ILD] disease and granulomatous lung disease [GLD] are rare respiratory disorders that have been associated with inflammatory bowel disease [IBD]. Clinical presentation is polymorphic and aetiology is unclear. METHODS: This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD, or drug-induced ILD/GLD, were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and the European Respiratory Society and on the discretion of reporting clinician. RESULTS: We identified 31 patients with ILD. The majority had ulcerative colitis [UC] [n = 22]. Drug-related ILD was found in 64% of these patients, 25 patients [80.6%] required hospitalisation, and one required non-invasive ventilation. The causative drug was stopped in all drug-related ILD, and 87% of patients received systemic steroids. At follow-up, 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, and there were no data in 13%. One patient was referred for lung transplantation, and one death from lung fibrosis was reported. We also identified 22 GLD patients: most had Crohn's disease [CD] [n = 17]. Drug-related GLD was found in 36% of patients and 10 patients [45.4%] required hospitalisation. The causative drug was stopped in all drug-related GLD, and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients. CONCLUSIONS: ILD and GLD, although rare, can cause significant morbidity. In our series, over half of cases were drug-related and therefore focused pharmacovigilance is needed to identify and manage these cases.

Published
2020

42. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era

Author

Nunes, T., Etchevers, M. J., Domènech, E., García-Sánchez, V., Ber, Y., Peñalva, M., Merino, O., Nos, P., Garcia-Planella, E., Casbas, A. G., Esteve, M., Samsó, Taxonera C., Huguet, Montoro M., Gisbert, J. P., Arranz, M. D.Martín, García-Sepulcre, M. F., de Acosta, Barreiro- M., Beltrán, B., Suárez, Alcaide N., Gismera, Saro C., Cabriada, J. L., Cañas-Ventura, A., Gomollón, F., and Panés, J.

Published
2013
Full Text
View/download PDF

45. OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

Author

Chaparro, M, primary, Garre, A, additional, Mesonero, F, additional, Rodríguez, C, additional, Barreiro-de Acosta, M, additional, Martínez-Cadilla, J, additional, Arroyo, M T, additional, Manceñido, N, additional, Sierra-Ausín, M, additional, Vera-Mendoza, I, additional, Casanova, M J, additional, Nos, P, additional, González-Muñoza, C, additional, Martínez, T, additional, Boscá-Watts, M, additional, Busquets, D, additional, Calafat, M, additional, Girona, E, additional, Llaó, J, additional, Martín-Arranz, M D, additional, Piqueras, M, additional, Ramos, L, additional, Suis, G, additional, Bermejo, F, additional, Carbajo, A Y, additional, Casas-Deza, D, additional, Fernández-Clotet, A, additional, García, M J, additional, Ginard, D, additional, Gutiérrez-Casbas, A, additional, Hernández-Villalba, L, additional, Lucendo, A J, additional, Márquez, L, additional, Merino-Ochoa, O, additional, Rancel, F J, additional, Taxonera, C, additional, López Sanromán, A, additional, Rubio, S, additional, Domènech, E, additional, and Gisbert, J P, additional

Published
2020
Full Text
View/download PDF

46. P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry

Author

Hernandez Camba, A, primary, Arranz, L, additional, Vera, I, additional, Carpio, D, additional, Calafat Sard, M, additional, Lucendo, A, additional, Taxonera, C, additional, Marín, S, additional, Garcia, M J, additional, Suris Marín, G, additional, Sánchez Rodríguez, E, additional, Carbajo, A Y, additional, De Castro, M L, additional, Iborra, M, additional, Martin-Cardona, A, additional, Rodríguez Lago, I, additional, Busquets, D, additional, Bertoletti, F, additional, Sierra Ausín, M, additional, Tardillo, C, additional, Huguet Malaves, J, additional, Bujanda, L, additional, Castaño, A, additional, Merino, O, additional, Domènch, E, additional, and Ramos, L, additional

Published
2020
Full Text
View/download PDF

50. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study

Author

Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutiérrez A, Gordillo Ábalos J, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodríguez-Lago I, Mesonero F, de Francisco R, Gómez-Gómez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Martín Arranz E, Cañete F, Vicente R, Sicilia B, Antolín B, Prieto V, Márquez L, Benítez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Pérez Calle JL, Van Domselaar M, Rodriguez C, Calvet X, Muñoz-Villafranca C, García-Sepulcre MF, Munoz-Garrido P, Fernández-Clotet A, Gómez Irwin L, Hernández S, Guardiola J, Sempere L, González Muñoza C, Hernández V, Beltrán B, Barrio J, Alba C, Moraleja I, López-Sanromán A, Riestra S, Martínez Montiel P, Garre A, Arranz L, García MJ, Martín Arranz MD, Corsino P, Arias L, Fernández-Salazar L, Fernández-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Arroyo Villarino MT, Mora M, Ruiz L, López-Serrano P, Blazquez I, Villoria A, Fernández M, Bermejo F, Banales JM, Domènech E, and Gisbert JP

Subjects
endocrine system diseases, digestive, oral, and skin physiology, inflammatory bowel disease, malignancy, primary sclerosing cholangitis, digestive system, digestive system diseases
Abstract

Primary sclerosing cholangitis (PSC) is usually associated with inflammatory bowel disease (IBD). An increased risk of malignancies, mainly colorectal cancer (CRC) and cholangiocarcinoma (CCA), has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results